Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity.
Liu H, Wu W, Sun G, Chia T, Cao L, Liu X, Guan J, Fu F, Yao Y, Wu Z, Zhou S, Wang J, Lu J, Kuang Z, Wu M, He L, Shao Z, Wu D, Chen B, Xu W, Wang Z, He K.
Liu H, et al. Among authors: guan j.
Cell Rep Med. 2022 Jun 21;3(6):100660. doi: 10.1016/j.xcrm.2022.100660.
Cell Rep Med. 2022.
PMID: 35732156
Free PMC article.